Literature DB >> 10768293

Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.

J W Gibbs1, S Sombati, R J DeLorenzo, D A Coulter.   

Abstract

PURPOSE: This study was undertaken to evaluate the effects of topiramate (TPM) on excitatory amino acid-evoked currents.
METHODS: Kainate and N-methyl-D-aspartate (NMDA) were applied to cultured rat hippocampal neurons by using a concentration-clamp apparatus to selectively activate the AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid)/kainate and NMDA receptor subtypes, respectively. The evoked membrane currents were recorded by using perforated-patch whole-cell voltage-clamp techniques.
RESULTS: TPM partially blocked kainate-evoked currents with an early-onset reversible phase (phase I) and a late-onset phase (phase II) that occurred after a 10- to 20-min delay and did not reverse during a 2-h washout period. Application of dibutyryl cyclic adenosine monophosphate (cAMP; 2 mM) during washout after phase II block enhanced reversal, with the kainate current amplitude being restored by approximately 50%. Phase II but not phase I block was prevented by prior application of okadaic acid (1 microM), a broad-spectrum phosphatase inhibitor, suggesting that phase II block may be mediated through interactions with intracellular intermediaries that alter the phosphorylation state of kainate-activated channels. Topiramate at 100 microM blocked kainate-evoked currents by 90% during phase II, but had no effect on NMDA-evoked currents. The median inhibitory concentration (IC50) values for phase I and II block of kainate currents were 1.6 and 4.8 microM, respectively, which are within the range of free serum levels of TPM in patients.
CONCLUSIONS: The specific blockade of the kainate-induced excitatory conductance is consistent with the ability of TPM to reduce neuronal excitability and could contribute to the anticonvulsant efficacy of this drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768293     DOI: 10.1111/j.1528-1157.2000.tb02164.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  79 in total

1.  Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice.

Authors:  Francisco Navarrete; José M Pérez-Ortiz; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0 T magnetic resonance spectroscopy study.

Authors:  Constance M Moore; Megan Wardrop; Blaise deB Frederick; Perry F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2006-08-31       Impact factor: 4.530

Review 3.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Improvement of cervico-trunco-brachial segmental dystonia with topiramate.

Authors:  Spiridon Papapetropoulos; Carlos Singer
Journal:  J Neurol       Date:  2005-11-22       Impact factor: 4.849

Review 5.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

6.  Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers.

Authors:  Mehmet Sofuoglu; James Poling; Maria Mouratidis; Thomas Kosten
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

7.  Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Erik W Gunderson; Heather M Haughey; Xin-Qun Wang; Lei Liu
Journal:  Addict Biol       Date:  2012-10-08       Impact factor: 4.280

8.  Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

Authors:  Henry R Kranzler; Jonathan Covault; Richard Feinn; Stephen Armeli; Howard Tennen; Albert J Arias; Joel Gelernter; Timothy Pond; Cheryl Oncken; Kyle M Kampman
Journal:  Am J Psychiatry       Date:  2014-04       Impact factor: 18.112

9.  Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature.

Authors:  Chasity M Shelton; Elizabeth L Alford; Stephanie Storgion; James Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

10.  The effects of topiramate on caspase-3 expression in hippocampus of basolateral amygdala (BLA) electrical kindled epilepsy rat.

Authors:  Xuqin Chen; Guanshui Bao; Ying Hua; Yan Li; Zhedong Wang; Xueguang Zhang
Journal:  J Mol Neurosci       Date:  2009-01-16       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.